Accelerating Antibody Development - A Proven Path from Gene to GMP Webinar
Abstract: Biopharma innovators face increasing pressure to advance monoclonal antibody programs to IND quickly without compromising product quality or downstream scalability. Yet, traditional timelines often extend beyond 12 months, creating delays that impact patient access and increase development costs. This webcast will explore how Catalent’s Rapid Antibody platform delivers GMP drug substance in as little as eight months, enabling IND readiness and first-in-human studies faster. Catalent’s expert, Laura Daley, PhD, will explain the integrated approach that combines robust cell line development and process optimization. This approach is supported by US-based GMP manufacturing, enabling aggressive timelines without sacrificing control or scalability.